Incanthera share price. For further enquiries: Incanthera plc.

PL Share price INC 27. Broker: Stanford Capital Partners Ltd Patrick Claridge/Tom Price/John Howes/Bob Pountney Ahead of the listing, Incanthera raised £1. 28: Mar 14, 2024 · Latest Incanthera PLC (INC:NXX) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more. June 3rd, 2024 Shareholders' Circular and Notice of General Meeting. The Company’s current lead product and focus is Sol, a potentially innovative Incanthera’s current focus is Skin + CELL, its luxury skincare brand, utilising ground-breaking formulation and delivery expertise, to bring scientifically proven formulations to cosmetics and unmet skincare solutions. Assess historical data, charts, technical analysis and contribute in the forum. Accordingly, the terms of the warrants issued in conjunction with the fundraising announced on 23 March 2021, have been amended such that they now expire on 12 April 2024 and have an exercise price of 10p. Incanthera is a UK-based, dermatology and oncology therapeutics company focusing on discovery and development of targeted solutions. 6% to the closing mid-market price of 12. A rich pipeline of future drug candidates provides the opportunities to develop in line with the business strategy. Aquis AQSE - Aquis AQSE Delayed price. Incanthera plc www. to the mid-price at close of trading on Friday, 31 May 2024 of 19p, with the Subscription comprising the issue of 17,403,681 new ordinary shares (“Subscription Shares”) representing 14. ward@incanthera. Incanthera plc (AQSE: INC), the specialist oncology company focused on innovative technologies in dermatology and oncology announces that it has issued 2,302,157 ordinary shares in the Company (“New Ordinary Shares”) at a price of 6. Aquis Exchange Corporate Adviser: Cairn Financial Advisers LLP ii: an abrdn business. com. June 21st, 2024 Admission of Subscription Shares Settlement of Subscription Funds. Suzanne Brocks, Head of Communications +44 (0) 7776 234600 suzanne. The Subscription and Sale Shares have been conducted at a price of 15p per share, a discount of 21 per cent. Aquis Exchange Corporate Adviser: Cairn Financial Advisers LLP The placing price represented a discount of 6. 85p last night, with the new shares including a warrant for one share at 20p. Suzanne Brocks, Head of Communications suzanne. Tim McCarthy, Chairman +44 (0) 7831 675747 tim. Board of Directors; Incanthera’s first License Deal was signed in Jul 11, 2024 · Latest Incanthera PLC (INC:NXX) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more. June 5th, 2024 ‘Aquis Leading Lights’ Presentation: June 2024. ADVFN Share Price Share Price Change Share Price % Change Low Price High Price Shares Traded; 05 Jun 2024: 24. 00 GBp. Global commercial deal for the launch of unique skincare brand Skin + CELL announced Dec 2023, expected to generate significant revenues and profitability in 2024 and beyond. com Tim McCarthy, Chairman tim. PL Share News; INC. 76 King Street. These deliver treatments specifically to a required Prepare technologies to valuation realisation. of the enlarged issued capital. 50 per share. Archive. com Incanthera plc www. Tim McCarthy, Chairman +44 (0 Incanthera PLC said it has filed a new patent application covering its Sol sun cream used to prevent a skin condition called solar keratosis and related cancers. Simon Ward, Chief Executive Officer +44 (0) 7747 625506 simon. Incanthera’s current focus is Skin + CELL, its The Company’s strategy of Acquire, Prepare, Commercialise is built on partnerships and academic relationships. Find the latest Incanthera plc (INC. Aquis Exchange Corporate Adviser: Cairn Financial Advisers LLP Investor Presentation. Incanthera’s unique skincare range will be launched under our luxury skincare brand Skin + CELL which will be available exclusively initially in Marionnaud’s stores in Switzerland and Austria from Q2 2024 with the roll out into the remaining 1,100 stores across European markets expected to follow thereafter in 2024. m. June 12th, 2024 Incanthera chairman discusses new director, Incanthera plc (AQSE:INC), the company specially focussed on innovative technologies in dermatology and oncology, advises that, further to its announcement on 17 April 2024, the final subscription proceeds of £25,833. As an integral part of the collaboration, upon signing the Heads of Terms, ImmuPharma has invested £2m into Incanthera by subscribing for 363,637 new ordinary Incanthera shares at a price of £5. The main country of operation is United Kingdom. July 5th, 2024 RNS Hotlist July 5: Blencowe, Coinsilium, Incanthera, SEEEN - Zaks Traders Cafe. Jul 12, 2024 · Stock analysis for Incanthera PLC (INC:Aquis AQSE) including stock price, stock chart, company news, key statistics, fundamentals and company profile. 18. Broker: Stanford Capital Partners Ltd Patrick Claridge/Tom Price/John Howes/Bob Pountney Sep 30, 2020 · These announcements have been well received by investors and the market, and we have seen a positive share price performance as a result. 9 per cent. 14; Suzanne. 95 pence per share, to service providers in lieu of contractual amounts owed totalling approximately £75,000 ("Fee Shares"). Shareholder: Number of shares held % of issued share capital: Tyndall Investment Management. com We would love to hear from you! Please fill out this form and we will get in touch with you shortly. Incanthera plc (AQSE:INC), the company specially focussed on innovative technologies in dermatology and oncology, announces it has received further warrant exercise notices over 5,166,667 new ordinary shares in the Company, at an exercise price of 10 pence per share (the “Warrant Shares”), providing the Company with gross proceeds of £516,666. com +44 (0) 7831 675747 Simon Ward, Chief Executive Officer simon. Currency in GBp (0. 14; Corporate Governance; Company Contact Details Incanthera plc (AQSE: INC), the specialist oncology company focused on transforming cancer treatment, is pleased to announce that it has raised gross proceeds of £1,144,650 through an oversubscribed placing of 9,538,750 new ordinary shares (“Placing Shares”) with existing and new investors at a price of 12 pence per share (“Issue Price”). incanthera. com Jun 21, 2024 · Shareholder Information. com Head Office: Incanthera plc 76 King Street Manchester M2 4NH, UK T: 0161 817 5005 E:info@incanthera. Shares in the company closed down 2. There are no restrictions on the transfer of AQSE Securities. 16,164,540. Incanthera Share Price; Incanthera Live Share Price; Incanthera Live Share Price (INC. The Company will provide a live presentation of its results via the Investor Meet Company (“IMC”) platform on Tuesday 8 December at 12. 50 GBp. Corporate Governance Report; QCA Corporate Governance Principles; Company Contact Details; News Shares Investor Evening in Partnership with AJ Bell Incanthera plc (AQSE:INC), the company specially focussed on innovative technologies in dermatology and oncology, announces that it will be presenting at Shares Investor Evening in partnership with AJ Bell, in London at 5. PL) INC. (Alliance News) - Incanthera PLC on Friday said it has raised GBP2. 1million, as announced 3 June 2024 oN AQSE Growth Market (AQSE: INC). 5% to 23. 2023. On 25 July 2023, 360,000 ordinary shares of 2p were issued at a price of 6. News; Press Coverage; Scientific Publications; Contact Us; Sustainability 2 days ago · Incanthera Share Chat. 30 p. Incanthera PLC has received positive data from a skin sensitisation study of its Sol skin cancer technology, which demonstrate it is “non-irritant”. View share price, share charts, recent trades, company information, news, financial results, research and more Financial Calendar. 95p per share to Dr Simon Ward, a Director, generating proceeds of £32,000. Principle 5: Maintain the Board as a well-functioning, balanced team led by the Chair. Share price and tools; Financial calendar; Shareholder information. Head Office: Incanthera Ltd. Established from the Institute of Cancer Therapeutics (ICT) at the University of Bradford, Incanthera retains its active involvement and discussion with the evolution of technologies from the ICT and has an exclusive Pipeline Agreement offering first right to all oncology IP . simon. 14; Corporate Governance; Company Contact Details Incanthera plc www. Download PDF. These deliver treatments specifically to a required Share price and tools. Incanthera plc. The Directors of Incanthera accept responsibility for this announcement. AQ) stock quote, history, news and other vital information to help you with your stock trading and investing. Post. 25m, with approximately 116. Incanthera plc (AQSE: INC) is pleased to announce that it will report its interim results for the six months ended 30 September 2020, on Tuesday 8 December 2020. 4 million shares. 14; Corporate Governance; Company Contact Details; News & media. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions. Incanthera PLC is a UK-based, dermatology and oncology therapeutics company focusing on drug discovery and development Share price INC 25. Share price INC 25. PL. PL Share Trades 1; INC. Manchester. Suzanne Brocks 07776 234600 Note to Editors About Incanthera Limited Mar 31, 2023 · On 5 April 2023, warrants issued in conjunction with the fundraising on 31 March 2021, have been amended such that they now expire on the 12 April 2024 and have an exercise price of 10p. Commercialise through a partner, securing a deal that aims to prioritise further development, marketing and early revenue to Incanthera. Shareholder Information; AGM; GM; Analyst coverage; Investor and Advisor contacts; AQSE Growth Market Rule 4. Unicorn Incanthera has also rights to a portfolio of ICT’s other cancer-targeting therapeutics and will use partnerships to take other candidates from this portfolio to market. Incanthera plc (AQSE:INC), the company specially focussed on innovative technologies in dermatology and oncology, announces that it will be presenting at Proactive’s One2One Investor Forum in London at 6pm today (16 May 2024) to an audience of high net worth investors, fund managers, private client brokers and analysts. brocks Incanthera Recent Trades. Aquis Exchange Corporate Adviser: Cairn Financial Advisers LLP simon. View real-time INC stock price and news, along with industry-best analysis. electronic versions of the materials you are seeking to access are being made available on this website in good faith and are for information purposes only. Tim McCarthy, chairman, said: “The company is delighted at the results of this placing and the support from existing and new shareholders, at an important time for Incanthera. PL Live RNS; INC. ISIN. Incanthera PLC is a UK-based, dermatology and oncology therapeutics company focusing on drug discovery and development Incanthera is a UK-based, dermatology and oncology therapeutics company focusing on discovery and development of targeted solutions. Incanthera Plc is listed on the Aquis Stock Exchange trading with ticker code INC. 6 million through a subscription of shares. 095 per ordinary share valid until 06 September 2023. Chat About INC. Tim McCarthy, Executive Chairman 07831 675747. Free forex prices, toplists, indices and lots more. Identify (in active negotiations) potential Head Office: Incanthera Ltd 76 King Street Manchester M2 4NH, UK T: 0161 817 5005 E:info@incanthera. Aim-listed biotech Immupharma PLC ( LON:IMM ) has an 11. GB00BGL7YW15. Incanthera PLC Share Price and News. T: 0161 817 5005. Our financial position is precisely on budget due to strong financial control and management, with reduced operating losses for the period of £471k, down from £485k in 2019. View the real-time Incanthera PLC (AQUIS INCIN) share price. The Manchester-based oncology and dermatology treatments manufacturer said it has raised GBP2. 2138002HEV4UFBOEXQ97. What we do; Our strategy; Market opportunity Simon is a co-founder of Incanthera and has more than 30 years’ senior Share price INC 32. E: info@incanthera. Complete Incanthera PLC stock information by Barron's. abrdn is a global investment company that helps customers plan, save and invest for their future. 95 pence per share to service providers in lieu of contractual amounts owed. 30 have now been received in connection with further warrant exercises over 258,333 new ordinary shares (“Further Warrant The placing price represented a discount of 6. 9% stake and warrants at the listing price of 9. View share price. PL Trade Information. The Company adopted the Schemes in Incanthera plc www. The Company has developed sophisticated formulation and targeting technology platforms to address previously unavailable options across dermatology and oncology. 01 GBP) As of 09:00AM BST. www. 00: 4. LEI code. Sol is a proprietary topical formulation designed to deliver an active agent into the skin that is known to prevent the formation of solar (actinic) keratosis and skin cancer. 85%. Share price chart; Detailed share price; Financial calendar; Shareholder information; Investor and Advisor contacts; AQSE Growth Market Rule 4. Aquis Exchange Corporate Adviser: Cairn Financial Advisers LLP Jo Global Commerical Deal. Our history. Regulatory News. 6 pence each in On 26 February 2020, prior to the Company’s admission to the AQSE Growth Market, the Company entered into a warrant agreement with Immupharma plc entitling Immupharma plc to subscribe for 7,272,740 ordinary shares (“Warrants”) at an exercise price of £0. M2 4NH, UK. 6 million through a subscription of 17. Incanthera announces commercial deal for its luxury skincare brand, Skin + CELL, with Marionnaud (Switzerland), part of AS Watson Group, the world’s largest health and beauty retailer with over 16,000 stores globally. Montgomery Communications. PL Share Price; INC. Share price INC 27. Jun 25, 2024 · Incanthera (INC) share price, charts, trades & the UK's most popular discussion forums. brocks@incanthera. com +44 (0) 7747 625506 Suzanne Brocks, Head of Communications suzanne. July 5th, 2024 Incanthera to host investor evening at historic City venue. What we do; Our strategy; Market opportunity; Our team. December 21st , 2023 Half-yearly results for the six months ended 30 September 2023; October 03rd , 2023 Notice of Annual General Meeting 2023 and Posting of Annual Report and Accounts May 7, 2024 · See the latest Incanthera PLC Ordinary Shares stock price (INC:AQSE), related news, valuation, dividends and more to help you make your investing decisions. INC. 4 days ago · Share price 28p Market cap £32m Share price performance 1 yr Source: Aquis Company description Founded as a spin-out from the Institute of Cancer Therapeutics at the Incanthera is a UK-based specialist in dermatological cancer treatments. Incanthera plc's shares are traded on the Access Segment of AQSE Exchange Growth Market, Updated as of 21 June 2024. com +44 (0) 7747 625506. July 5th, 2024 Investor Evening - Aquis Stock Exchange and Investor Hub. 2022. Jun 14, 2024 · Incanthera plc (INC) Company Page. Jun 26, 2024 · Incanthera’s Skincare Range . Share price chart; Detailed share price; Financial calendar; Shareholder information. It has a market capitalisation of £33. on Tuesday 18 June 2024 to an audience of high net worth investors, fund managers, private client brokers and Mar 25, 2024 · Share price and tools; Financial calendar; Shareholder information; Investor and Advisor contacts; March 25th, 2024 Incanthera plc - Breakthrough Distribution Deal. Aquis Exchange Corporate Adviser: Cairn Financial Advisers LLP Jo Turner/James Lewis Incanthera plc has adopted and operates a share dealing code governing the share dealings of the directors of the Company and applicable employees with a view to ensuring compliance with the AQSE Growth Market Rules. For further information, please contact: Tim McCarthy, Chairman +44 (0) 7831 675747 tim. 2024. July 11th, 2024 Commercial Order Update. 14; Corporate Governance. 13. 14; Corporate Governance; Company Contact Details A General Meeting of Incanthera plc has been convened, following an Institutional-led Subscription and Sale Shares totalling £4. June 26th, 2024 Tim McCarthy at Shares Magazine Investor Presentation. PL Share Chat; INC. Share price INC 32. Recent Share Trades, updated throught the trading day for Incanthera Plc Incanthera Share Discussion Threads. June 12th, 2024 Incanthera chairman discusses new director, strategic fundraising and Aquis promotion. This investment values Incanthera at a pre-money valuation of approximately £10m and is consistent with the most recent funding round View today's Incanthera PLC stock price and latest INCIN news and analysis. Symbol: INC. Showing 851 to 871 of 875 messages Another placing with funds no doubt lining the directors pockets with a share price Jun 13, 2024 · The Company is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. Share price and tools. mccarthy@incanthera. com +44 (0) 7776 234600. For further enquiries: Incanthera plc. NWF (Biomedical) LP. June 10th, 2024 Incanthera appoints John Howes as independent Incanthera’s Skincare Range . If granted, it will further extend the life of the patent family protecting Sol to 2041. Incanthera plc announces that it has adopted both an approved and unapproved share option scheme (the “Schemes”) and, on 4 th July 2020, made a grant of options under both Schemes to directors and others. July 4th, 2024 Top Five Aquis stocks in the first half of 2024. Aquis Exchange Corporate Adviser: Cairn Financial Advisers LLP Jo Turner/James Lewis/Mark Rogers +44 (0) 20 7213 0880. Incanthera price history. Share price chart; Detailed share price; Financial calendar; Incanthera (INC) - Simon Ward: CEO, Tim McCarthy: Chairman, Suzanne Brocks The Company's current focus is a range of dermatological applications utilising its unique formulation and delivery technologies to meet cosmetic unmet needs. June 12th, 2024 Incanthera chairman discusses new director, Press Coverage. What we do; Our strategy the technology within Incanthera’s portfolio is dedicated to enhancing the outcomes of patients by Jun 21, 2024 · 21st Jun 2024 17:17. 5p from new institutional investors, existing shareholders and management, money that has been earmarked to fund the development of Sol, its novel cream to treat and prevent skin cancer. PL Shares - Stock Quote, Charts, Trade History, Share Chat, Financial Terms Glossary. Jul 11, 2024 · Incanthera Share Chat. Create real-time notifications to follow any changes in the live stock price. Simon Ward, Chief Executive Officer 07747 625506. June 26th, 2024 Investor Presentation; June 25th, 2024 Holding(s) in Company Share price and tools. May 16th, 2024 Investor Presentation; April 25th, 2024 Holding(s) in Company For the purposes of the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority (“DTR”), the Board of Incanthera hereby notifies the market that following admission, the Company’s total issued share capital will consist of 64,544,121 ordinary shares with a nominal value of 2p each per share. We would love to hear from you! Please fill out this form and we will get in touch with you shortly. June 20th, 2024 Result of General Meeting. View article. About us. 70. 2mn at 9. Market open. 68m shares in issue. 21,667,518. The General Meeting is required to consider Resolutions required to grant authorities to issue Subscription Shares. 5p plus an option to subscribe for a further £250,000 worth of shares Included in the initial application for Admission of the Investment Shares were 1,079,138 new ordinary shares, issued at the same price as the Investment Shares of 6. Share price chart; Simon is a co-founder of Incanthera and has more than 30 years’ senior experience in academia and business. Latest from Incanthera. The skincare market is vast and growing rapidly with global revenues projected to reach $180 billion by 2024. 14; Corporate Governance; Company Contact Details tim. Incanthera 0161 817 5005. 57%. Share price and tools; Financial calendar; Shareholder information; Investor and Advisor contacts; AQSE Growth Market Rule 4. 14; Share; Latest from Incanthera Incanthera plc, the specialist company focused on dermatology and oncology announces the grant of 3,200,000 options, on 21 February 2024, to directors, senior management and employees under both its approved and unapproved share option schemes (the "Schemes") as follows: Option Schemes and Grant of Options. Suzanne Brocks, Head of Communications +44 (0) 7776 234600 Share price and tools. jp uo zy xh nx vp he vx va dd